Devashish Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Devashish Mehta has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Avinash Bajaj
Laboratory of Tumour Immune Microenvironment (TIME), Regional Centre for Biotechnology, 3(rd) Milestone Faridabad Gurgaon Expressway, Faridabad 121001, India
19 shared publications Varsha Saini
Laboratory of Nanotechnology and Chemical Biology Regional Centre for Biotechnology 3rd Milestone, Faridabad‐Gurgaon Expressway, NCR Biotech Cluster Faridabad Haryana 121001 India
8 shared publicationsDolly Jain
Laboratory of Tumour Immune Microenvironment, Regional Centre for Biotechnology, Third Milestone, Faridabad-Gurgaon Expressway, NCR Biotech Science Cluster, Faridabad 121001, India
7 shared publications- Somesh Kumar Jha
Laboratory of Tumour Immune Microenvironment, Regional Centre for Biotechnology, Third Milestone, Faridabad-Gurgaon Expressway, NCR Biotech Science Cluster, Faridabad 121001, India
6 shared publications - Ujjaini Dasgupta
Amity Institute of Integrative Sciences and Health, Amity University Haryana, Panchgaon, Manesar, Gurgaon-122413, Haryana, India
6 shared publications Amit Arora
Department of Chemistry Guru Jambheshwar University of Science and Technology Hisar Haryana 125001 India
5 shared publications
Latest Publications
- 27 March 2026
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 38 (7) , 3112-3132
Engineered Nanomicelles Prevent Colorectal Liver Metastasis via Inhibiting the Premetastatic Niche and Regulating the Metabolic Homeostasis
- 27 March 2026
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 38 (7) , 3112-3132
Engineered Nanomicelles Prevent Colorectal Liver Metastasis via Inhibiting the Premetastatic Niche and Regulating the Metabolic Homeostasis
- 4 December 2025
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (24) , 9646-9664
A Biologically Inert Tamoxifen-Derived Long-Lasting Hydrogel-Mediated Immunochemotherapy Can Mitigate Tumor Progression and Activate T Cell Immunity
The immunosuppressive tumour microenvironment (TME) is often regarded as the Achilles heel of cancer therapy, as it can limit immune cell infiltration and therapeutic efficacy. To address this, we engineered a long-lasting tetrapeptide-conjugated lithocholic acid-tamoxifen-derived injectable hydrogel (LTG4-Gel) that, upon implantation, does not exert any systemic toxicity in mice, rats and rabbits. LTG4-Gel retained its injectability and rheological flow properties even after the entrapment of multiple drugs, as confirmed by rheology, UV absorption, circular dichroism and atomic force microscopy. Doxorubicin (DOX) entrapped hydrogel (DOX-Gel) significantly induced the anti-tumour responses with enhanced survival in different syngeneic murine tumour models. We further showed that the engineered chimeric gel, upon entrapment of DOX and an immune agonist (c-di-GMP sodium salt (GMP)) (DOX-GMP-Gel), targeting the STING (stimulator of interferon gene) pathway, effectively mitigates tumour progression and increases survival across different tumour models. We demonstrated that DOX-GMP-Gel therapy activates the antitumour T cell immunity and generates a memory response to clear distant tumours. Our study provides a systemic design of long-lasting low molecular hydrogel to deliver the combination of immunostimulatory adjuvants and immunogenic cell death-inducing agents, offering a promising approach to modulate the tumour microenvironment for enhanced cancer therapy.
- 4 December 2025
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (24) , 9646-9664
A Biologically Inert Tamoxifen-Derived Long-Lasting Hydrogel-Mediated Immunochemotherapy Can Mitigate Tumor Progression and Activate T Cell Immunity
The immunosuppressive tumour microenvironment (TME) is often regarded as the Achilles heel of cancer therapy, as it can limit immune cell infiltration and therapeutic efficacy. To address this, we engineered a long-lasting tetrapeptide-conjugated lithocholic acid-tamoxifen-derived injectable hydrogel (LTG4-Gel) that, upon implantation, does not exert any systemic toxicity in mice, rats and rabbits. LTG4-Gel retained its injectability and rheological flow properties even after the entrapment of multiple drugs, as confirmed by rheology, UV absorption, circular dichroism and atomic force microscopy. Doxorubicin (DOX) entrapped hydrogel (DOX-Gel) significantly induced the anti-tumour responses with enhanced survival in different syngeneic murine tumour models. We further showed that the engineered chimeric gel, upon entrapment of DOX and an immune agonist (c-di-GMP sodium salt (GMP)) (DOX-GMP-Gel), targeting the STING (stimulator of interferon gene) pathway, effectively mitigates tumour progression and increases survival across different tumour models. We demonstrated that DOX-GMP-Gel therapy activates the antitumour T cell immunity and generates a memory response to clear distant tumours. Our study provides a systemic design of long-lasting low molecular hydrogel to deliver the combination of immunostimulatory adjuvants and immunogenic cell death-inducing agents, offering a promising approach to modulate the tumour microenvironment for enhanced cancer therapy.
- 14 September 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (22) , e202500174
Aspirin‐Conjugated Cholic Acid Derivative Combats Polymicrobial Infections and Inflammation
Treating wound infections caused by Gram‐positive and Gram‐negative bacteria, along with associated inflammation, remains challenging due to the limited therapeutic efficacy of conventional antibiotics. Leveraging the unique properties of cholic acid derivatives, such as their cationic nature, hydrophobicity, and structural adaptability, a novel aspirin‐derived facile amphiphile based on cholic acid (amphiphile 1 ) is designed and synthesized. The investigations reveal that the amphiphile 1 functions as a bacterial membrane disruptor through interacting with key components such as lipoteichoic acid and lipopolysaccharide of bacterial membranes. It is observed that amphiphile 1 can degrade both monomicrobial and polymicrobial preformed biofilms originating from Gram‐positive and Gram‐negative bacteria. Animal studies demonstrate that hydrogel‐based delivery of amphiphile 1 effectively mitigates bacterial infections and resolves bacterial‐associated inflammation. Collectively, these findings underscore that amphiphile 1 is a putative therapeutic agent for addressing the challenges of polymicrobial infections.
- 14 September 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (22) , e202500174
Aspirin‐Conjugated Cholic Acid Derivative Combats Polymicrobial Infections and Inflammation
Treating wound infections caused by Gram‐positive and Gram‐negative bacteria, along with associated inflammation, remains challenging due to the limited therapeutic efficacy of conventional antibiotics. Leveraging the unique properties of cholic acid derivatives, such as their cationic nature, hydrophobicity, and structural adaptability, a novel aspirin‐derived facile amphiphile based on cholic acid (amphiphile 1 ) is designed and synthesized. The investigations reveal that the amphiphile 1 functions as a bacterial membrane disruptor through interacting with key components such as lipoteichoic acid and lipopolysaccharide of bacterial membranes. It is observed that amphiphile 1 can degrade both monomicrobial and polymicrobial preformed biofilms originating from Gram‐positive and Gram‐negative bacteria. Animal studies demonstrate that hydrogel‐based delivery of amphiphile 1 effectively mitigates bacterial infections and resolves bacterial‐associated inflammation. Collectively, these findings underscore that amphiphile 1 is a putative therapeutic agent for addressing the challenges of polymicrobial infections.
- 13 May 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (6) , 1271-1295
Recent Advances in the Development of Antifungal Agents: Beyond Azoles, Polyenes, and Echinocandins
The escalating incidence of antimicrobial resistance to antifungal agents, alongside the emergence of drug-resistant fungal strains, constitutes a significant threat to a potential global fungal pandemic. In response, researchers are intensifying efforts to identify novel antifungal compounds through diverse methodologies. Emerging strategies focus on innovative therapeutic targets that may reduce the risk of resistance development while offering broad-spectrum efficacy against fungal infections. Additionally, these approaches present potential cost-effectiveness and accelerated development timelines. This review systematically categorizes a range of novel antifungal compounds, including antifungal peptides, cationic amphiphiles, small molecules, polymers, and repurposed drugs, based on their efficacy in inhibiting fungal growth and associated virulence factors. These compounds exhibit notable antimicrobial activity across in silico, in vitro, and in vivo systems against various pathogenic fungal strains, with several showing substantial promise for clinical application. Furthermore, the review highlights the limitations of standard antifungals and elucidates the mechanisms by which fungal strains develop resistance. This work aims to engage researchers in the distinctive field of fungal biology and foster the exploration of new antifungal strategies.
- 13 May 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (6) , 1271-1295
Recent Advances in the Development of Antifungal Agents: Beyond Azoles, Polyenes, and Echinocandins
The escalating incidence of antimicrobial resistance to antifungal agents, alongside the emergence of drug-resistant fungal strains, constitutes a significant threat to a potential global fungal pandemic. In response, researchers are intensifying efforts to identify novel antifungal compounds through diverse methodologies. Emerging strategies focus on innovative therapeutic targets that may reduce the risk of resistance development while offering broad-spectrum efficacy against fungal infections. Additionally, these approaches present potential cost-effectiveness and accelerated development timelines. This review systematically categorizes a range of novel antifungal compounds, including antifungal peptides, cationic amphiphiles, small molecules, polymers, and repurposed drugs, based on their efficacy in inhibiting fungal growth and associated virulence factors. These compounds exhibit notable antimicrobial activity across in silico, in vitro, and in vivo systems against various pathogenic fungal strains, with several showing substantial promise for clinical application. Furthermore, the review highlights the limitations of standard antifungals and elucidates the mechanisms by which fungal strains develop resistance. This work aims to engage researchers in the distinctive field of fungal biology and foster the exploration of new antifungal strategies.
- Open Access
- 4 February 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (7) , 2003-2010
Docetaxel-conjugated bile acid-derived nanomicelles can inhibit tumour progression with reduced toxicity
In this study, we aimed to enhance the tolerability and reduce the toxic effects of DTX by developing a novel hybrid scaffold (PIP-LCA-DTX), where we conjugated DTX to piperidine-derived lithocholic acid.
- 4 February 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (7) , 2003-2010
Open AccessDocetaxel-conjugated bile acid-derived nanomicelles can inhibit tumour progression with reduced toxicity
In this study, we aimed to enhance the tolerability and reduce the toxic effects of DTX by developing a novel hybrid scaffold (PIP-LCA-DTX), where we conjugated DTX to piperidine-derived lithocholic acid.
- 27 November 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 3758-3779
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies
The mechanistic target of rapamycin kinase (MTOR) is pivotal for cell growth, metabolism, and survival. It functions through two distinct complexes, mechanistic TORC1 and mechanistic TORC2 (mTORC1 and mTORC2). These complexes function in the development and progression of cancer by regulating different cellular processes, such as protein synthesis, lipid metabolism, and glucose homeostasis. The mTORC1 complex senses nutrients and initiates proliferative signals, and mTORC2 is crucial for cell survival and cytoskeletal rearrangements. mTORC1 and mTORC2 have therefore emerged as potential targets for cancer treatment. Several mTOR inhibitors, including rapamycin and its analogs (rapalogs), primarily target mTORC1 and are effective for specific cancer types. However, these inhibitors often lead to resistance and limited long-term advantages due to the activation of survival pathways through feedback mechanisms. Researchers have created next-generation inhibitors targeting mTORC1 and mTORC2 and dual PI3K/mTOR inhibitors to address these difficulties. These inhibitors demonstrate enhanced anti-tumor effects by simultaneously disrupting multiple signaling pathways and show promise for improved and long-lasting therapies. However, development of resistance and adverse side effects remain a significant obstacle. Recent additions known as RapaLinks have emerged as a boon to counter drug-resistant cancer cells, as they are more potent and provide a more comprehensive blockade of mTOR signaling pathways. This Review combines current research findings and clinical insights to enhance our understanding of the crucial role of mTOR signaling in cancer biology and highlights the evolution of mTOR inhibitors as promising therapeutic approaches.
- 27 November 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (12) , 3758-3779
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies
The mechanistic target of rapamycin kinase (MTOR) is pivotal for cell growth, metabolism, and survival. It functions through two distinct complexes, mechanistic TORC1 and mechanistic TORC2 (mTORC1 and mTORC2). These complexes function in the development and progression of cancer by regulating different cellular processes, such as protein synthesis, lipid metabolism, and glucose homeostasis. The mTORC1 complex senses nutrients and initiates proliferative signals, and mTORC2 is crucial for cell survival and cytoskeletal rearrangements. mTORC1 and mTORC2 have therefore emerged as potential targets for cancer treatment. Several mTOR inhibitors, including rapamycin and its analogs (rapalogs), primarily target mTORC1 and are effective for specific cancer types. However, these inhibitors often lead to resistance and limited long-term advantages due to the activation of survival pathways through feedback mechanisms. Researchers have created next-generation inhibitors targeting mTORC1 and mTORC2 and dual PI3K/mTOR inhibitors to address these difficulties. These inhibitors demonstrate enhanced anti-tumor effects by simultaneously disrupting multiple signaling pathways and show promise for improved and long-lasting therapies. However, development of resistance and adverse side effects remain a significant obstacle. Recent additions known as RapaLinks have emerged as a boon to counter drug-resistant cancer cells, as they are more potent and provide a more comprehensive blockade of mTOR signaling pathways. This Review combines current research findings and clinical insights to enhance our understanding of the crucial role of mTOR signaling in cancer biology and highlights the evolution of mTOR inhibitors as promising therapeutic approaches.
- 20 November 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (12) , 4146-4155
Niacin-Cholic Acid-Peptide Conjugate Act as a Potential Antibiotic Adjuvant to Mitigate Polymicrobial Infections Caused by Gram-Negative Pathogens
Polymicrobial wound infections caused by Gram-negative bacteria and associated inflammation are challenging to manage, as many antibiotics do not work against these infections. Utilizing adjuvants to repurpose the existing antibiotics for mitigating microbial infections presents an alternative therapeutic strategy. We designed and developed a niacin-cholic acid-peptide conjugate (1) to rejuvenate the therapeutic efficacy of macrolide antibiotics against Gram-negative pathogens. We conjugated niacin with anti-inflammatory properties at the carboxyl terminal of the cholic acid and dipeptide (glycine-valine) at the three hydroxyl terminals of cholic acid to obtain the amphiphile 1. Our findings demonstrated that amphiphile 1 serves as a microbial membrane disruptor that facilitates the entry of erythromycin (ERY) in bacterial cells. The combination of amphiphile 1 and ERY is bactericidal and can effectively eliminate monomicrobial and polymicrobial Gram-negative bacterial biofilms. We further demonstrated the antibacterial effectiveness of combining 1 and ERY against monomicrobial and polymicrobial wound infections. Together, these findings indicate that amphiphile 1 revitalizes the remedial efficacy of ERY against Gram-negative bacteria.
- 20 November 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (12) , 4146-4155
Niacin-Cholic Acid-Peptide Conjugate Act as a Potential Antibiotic Adjuvant to Mitigate Polymicrobial Infections Caused by Gram-Negative Pathogens
Polymicrobial wound infections caused by Gram-negative bacteria and associated inflammation are challenging to manage, as many antibiotics do not work against these infections. Utilizing adjuvants to repurpose the existing antibiotics for mitigating microbial infections presents an alternative therapeutic strategy. We designed and developed a niacin-cholic acid-peptide conjugate (1) to rejuvenate the therapeutic efficacy of macrolide antibiotics against Gram-negative pathogens. We conjugated niacin with anti-inflammatory properties at the carboxyl terminal of the cholic acid and dipeptide (glycine-valine) at the three hydroxyl terminals of cholic acid to obtain the amphiphile 1. Our findings demonstrated that amphiphile 1 serves as a microbial membrane disruptor that facilitates the entry of erythromycin (ERY) in bacterial cells. The combination of amphiphile 1 and ERY is bactericidal and can effectively eliminate monomicrobial and polymicrobial Gram-negative bacterial biofilms. We further demonstrated the antibacterial effectiveness of combining 1 and ERY against monomicrobial and polymicrobial wound infections. Together, these findings indicate that amphiphile 1 revitalizes the remedial efficacy of ERY against Gram-negative bacteria.
- Open Access
- 1 May 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (21) , 10350-10365
Engineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate
Tumour cells secrete various proangiogenic factors like VEGF, PDGF, and EGF that result in the formation of highly vascularized tumours with an immunosuppressive tumour microenvironment.
- 1 May 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (21) , 10350-10365
Open AccessEngineered nanomicelles targeting proliferation and angiogenesis inhibit tumour progression by impairing the synthesis of ceramide-1-phosphate
Tumour cells secrete various proangiogenic factors like VEGF, PDGF, and EGF that result in the formation of highly vascularized tumours with an immunosuppressive tumour microenvironment.
- 31 January 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (2) , 527-540
Xanthone Derivatives Enhance the Therapeutic Potential of Neomycin against Polymicrobial Gram-Negative Bacterial Infections
Gram-negative bacterial infections are difficult to manage as many antibiotics are ineffective owing to the presence of impermeable bacterial membranes. Polymicrobial infections pose a serious threat due to the inadequate efficacy of available antibiotics, thereby necessitating the administration of antibiotics at higher doses. Antibiotic adjuvants have emerged as a boon as they can augment the therapeutic potential of available antibiotics. However, the toxicity profile of antibiotic adjuvants is a major hurdle in clinical translation. Here, we report the design, synthesis, and biological activities of xanthone-derived molecules as potential antibiotic adjuvants. Our SAR studies witnessed that the p-dimethylamino pyridine-derivative of xanthone (X8) enhances the efficacy of neomycin (NEO) against Escherichia coli and Pseudomonas aeruginosa and causes a synergistic antimicrobial effect without any toxicity against mammalian cells. Biochemical studies suggest that the combination of X8 and NEO, apart from inhibiting protein synthesis, enhances the membrane permeability by binding to lipopolysaccharide. Notably, the combination of X8 and NEO can disrupt the monomicrobial and polymicrobial biofilms and show promising therapeutic potential against a murine wound infection model. Collectively, our results unveil the combination of X8 and NEO as a suitable adjuvant therapy for the inhibition of the Gram-negative bacterial infections.
- 31 January 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (2) , 527-540
Xanthone Derivatives Enhance the Therapeutic Potential of Neomycin against Polymicrobial Gram-Negative Bacterial Infections
Gram-negative bacterial infections are difficult to manage as many antibiotics are ineffective owing to the presence of impermeable bacterial membranes. Polymicrobial infections pose a serious threat due to the inadequate efficacy of available antibiotics, thereby necessitating the administration of antibiotics at higher doses. Antibiotic adjuvants have emerged as a boon as they can augment the therapeutic potential of available antibiotics. However, the toxicity profile of antibiotic adjuvants is a major hurdle in clinical translation. Here, we report the design, synthesis, and biological activities of xanthone-derived molecules as potential antibiotic adjuvants. Our SAR studies witnessed that the p-dimethylamino pyridine-derivative of xanthone (X8) enhances the efficacy of neomycin (NEO) against Escherichia coli and Pseudomonas aeruginosa and causes a synergistic antimicrobial effect without any toxicity against mammalian cells. Biochemical studies suggest that the combination of X8 and NEO, apart from inhibiting protein synthesis, enhances the membrane permeability by binding to lipopolysaccharide. Notably, the combination of X8 and NEO can disrupt the monomicrobial and polymicrobial biofilms and show promising therapeutic potential against a murine wound infection model. Collectively, our results unveil the combination of X8 and NEO as a suitable adjuvant therapy for the inhibition of the Gram-negative bacterial infections.
- 26 December 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (1) , 138-154
Cholic Acid-Derived Gemini Amphiphile Can Eradicate Interkingdom Polymicrobial Biofilms and Wound Infections
Biofilm infections are mainly caused by Gram-positive bacteria (GPB) like Staphylococcus aureus, Gram-negative bacteria (GNB) like Pseudomonas aeruginosa, and fungi like Candida albicans. These infections are responsible for antimicrobial tolerance, and commensal interactions of these microbes pose a severe threat to chronic infections. Treatment therapies against biofilm infections are limited to eradicating only 20-30% of infections. Here, we present the synthesis of a series of bile acid-derived molecules using lithocholic acid, deoxycholic acid, and cholic acid where two bile acid molecules are tethered through 3'-hydroxyl or 24'-carboxyl terminals with varying spacer length (trimethylene, pentamethylene, octamethylene, and dodecamethylene). Our structure-activity relationship investigations revealed that G21, a cholic acid-derived gemini amphiphile having trimethylene spacer tethered through the C24 position, is a broad-spectrum antimicrobial agent. Biochemical studies witnessed that G21 interacts with negatively charged lipoteichoic acid, lipopolysaccharide, and phosphatidylcholine moieties of GPB, GNB, and fungi and disrupts the microbial cell membranes. We further demonstrated that G21 can eradicate polymicrobial biofilms and wound infections and prevent bacteria and fungi from developing drug resistance. Therefore, our findings revealed the potential of G21 as a versatile antimicrobial agent capable of effectively targeting polymicrobial biofilms and wound infections, suggesting that it is a promising antimicrobial agent for future applications.
- 26 December 2023
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (1) , 138-154
Cholic Acid-Derived Gemini Amphiphile Can Eradicate Interkingdom Polymicrobial Biofilms and Wound Infections
Biofilm infections are mainly caused by Gram-positive bacteria (GPB) like Staphylococcus aureus, Gram-negative bacteria (GNB) like Pseudomonas aeruginosa, and fungi like Candida albicans. These infections are responsible for antimicrobial tolerance, and commensal interactions of these microbes pose a severe threat to chronic infections. Treatment therapies against biofilm infections are limited to eradicating only 20-30% of infections. Here, we present the synthesis of a series of bile acid-derived molecules using lithocholic acid, deoxycholic acid, and cholic acid where two bile acid molecules are tethered through 3'-hydroxyl or 24'-carboxyl terminals with varying spacer length (trimethylene, pentamethylene, octamethylene, and dodecamethylene). Our structure-activity relationship investigations revealed that G21, a cholic acid-derived gemini amphiphile having trimethylene spacer tethered through the C24 position, is a broad-spectrum antimicrobial agent. Biochemical studies witnessed that G21 interacts with negatively charged lipoteichoic acid, lipopolysaccharide, and phosphatidylcholine moieties of GPB, GNB, and fungi and disrupts the microbial cell membranes. We further demonstrated that G21 can eradicate polymicrobial biofilms and wound infections and prevent bacteria and fungi from developing drug resistance. Therefore, our findings revealed the potential of G21 as a versatile antimicrobial agent capable of effectively targeting polymicrobial biofilms and wound infections, suggesting that it is a promising antimicrobial agent for future applications.